77,933 Shares in Inhibrx, Inc. (NASDAQ:INBX) Bought by Alpha Wealth Funds LLC

Alpha Wealth Funds LLC bought a new position in Inhibrx, Inc. (NASDAQ:INBX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 77,933 shares of the company's stock, valued at approximately $1,180,000. Inhibrx accounts for about 1.1% of Alpha Wealth Funds LLC's holdings, making the stock its 16th largest holding. Alpha Wealth Funds LLC owned about 0.54% of Inhibrx at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of INBX. Sanofi bought a new position in shares of Inhibrx in the fourth quarter worth about $17,832,000. HighTower Advisors LLC bought a new position in Inhibrx in the 4th quarter worth approximately $12,039,000. Walleye Capital LLC bought a new position in Inhibrx in the 4th quarter worth approximately $8,932,000. Slotnik Capital LLC bought a new position in Inhibrx in the 4th quarter worth approximately $5,975,000. Finally, Millennium Management LLC bought a new position in shares of Inhibrx during the fourth quarter worth $3,979,000. Institutional investors own 82.46% of the company's stock.

Inhibrx Stock Down 1.4%

Inhibrx stock traded down $0.19 during midday trading on Friday, reaching $13.56. 76,321 shares of the stock traded hands, compared to its average volume of 119,771. The stock's fifty day moving average is $12.40 and its 200-day moving average is $13.46. Inhibrx, Inc. has a 12 month low of $10.80 and a 12 month high of $18.95. The stock has a market cap of $196.29 million and a P/E ratio of 0.12.

Inhibrx (NASDAQ:INBX - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($2.80) EPS for the quarter, missing the consensus estimate of ($2.55) by ($0.25). On average, equities analysts predict that Inhibrx, Inc. will post 104.88 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, JMP Securities restated a "market perform" rating on shares of Inhibrx in a research report on Thursday, May 15th.

Inhibrx Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.